AN2 Therapeutics, Inc. (ANTX) — Analyst outlook / Analyst consensus target is. Based on 8 analyst ratings, the consensus is bullish — 5 Buy, 3 Hold.
The consensus price target is $7.75 (low: $2.00, high: $22.00), representing an upside of 160.1% from the current price $2.98.
Analysts estimate Earnings Per Share (EPS) of $-1.72 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.72 vs est $-1.72 (beat +0.2%). 2025: actual $-1.16 vs est $-1.12 (missed -3.6%). Analyst accuracy: 98%.
ANTX Stock — 12-Month Price Forecast
$7.75
▲ +160.07% Upside
Average Price Target
Based on 8 Wall Street analysts offering 12-month price targets for AN2 Therapeutics, Inc., the average price target is $7.75, with a high forecast of $22.00, and a low forecast of $2.00.
The average price target represents a +160.07% change from the last price of $2.98.
Highest Price Target
$22.00
Average Price Target
$7.75
Lowest Price Target
$2.00
ANTX Analyst Ratings
Buy
Based on 8 analysts giving stock ratings to AN2 Therapeutics, Inc. in the past 3 months
EPS Estimates — ANTX
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.72
vs Est –$1.72
▲ 0.2% off
2025
Actual –$1.16
vs Est –$1.12
▼ 3.4% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ANTX
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
